Interactions of moclobemide with concomitantly administered medication: evidence from pharmacological and clinical studies

@article{Amrein2005InteractionsOM,
  title={Interactions of moclobemide with concomitantly administered medication: evidence from pharmacological and clinical studies},
  author={R. Amrein and T. W. G{\"u}ntert and Jasper Dingemanse and Thomas Lorscheid and Max Stabl and W. Schmid-burgk},
  journal={Psychopharmacology},
  year={2005},
  volume={106},
  pages={S24-S31}
}
Interactions may occur on pharmacological or pharmacokinetic grounds. Both types of interactions are discussed in relationship with the pharmacological and pharmacokinetic data of moclobemide, a reversible MAO-inhibitor. A variety of interaction studies either designed more specifically as kinetic or as dynamic studies have been performed with moclobemide. The results of these studies are presented. In view of these results as well as in view of data stemming from clinical trials it can be… Expand
Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study.
TLDR
VPA does not significantly affect PK or metabolism ofMCB, whereas CBZ time-dependently decreases MCB exposure, probably by inducing metabolism of MCB and its major plasma metabolite. Expand
Moclobemide: therapeutic use and clinical studies.
  • U. Bonnet
  • Psychology, Medicine
  • CNS drug reviews
  • 2003
Moclobemide is a reversible inhibitor of monoamine-oxidase-A (RIMA) and has been extensively evaluated in the treatment of a wide spectrum of depressive disorders and less extensively studied inExpand
Food and Drug Interactions with Monoamine Oxidase Inhibitors
TLDR
The most feared interaction of MAOIs is the interaction with tyramine, a compound contained in a number of foods and beverages, which may lead to hypertensive crises and the so-called ‘cheese reaction’. Expand
Risk of seizures associated with psychotropic medications: emphasis on new drugs and new findings
TLDR
In this qualitative review, the authors provide an update on the most recently published reports on seizures associated with antidepressants, antipsychotics, mood stabilisers, anxiolytics and sedative-hypnotics. Expand
Moclobemide versus fluoxetine for a major depressive episode
TLDR
Doubling the low dosage in non-responders after 3 weeks resulted in a statistically significant improvement of CGI in the moclobemide group by comparison with the fluoxetine group at study end, suggesting that 600 mg moclopemide/day can still improve the patient's condition, while 40 mg fluoxettine/day does not. Expand
Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively
TLDR
Practical advice is given in terms of dietary restrictions, interactions with other medications, and how prescribers can stop and switch MAOIs, both within the drug class and outside of it. Expand
Evaluation of Single‐Point Sampling Strategies for the Estimation of Moclobemide Exposure in Depressive Patients
TLDR
As the most reliable surrogate for moclobemide systemic exposure, concentrations at 4 and 6 hours should be used instead of predose trough concentrations as an indicator of between‐patient variability and a guide for dose adjustments in specific clinical situations. Expand
Moclobemide twice daily in the treatment of major depressive episode: a double-blind, multicenter comparison with different three-times-daily dosage schedules.
TLDR
Tolerability was rated "good" or "excellent" in 94% of patients, and there was no appreciable change in vital signs in any of the treatment groups, suggesting that twice-daily moclobemide 150 mg b.i.d. is the optimal initial schedule for treatment of depression. Expand
▼Moclobemide for depression
TLDR
Moclobemide (Manerix - Roche), the first of a new class of antidepressant drugs, was launched in the UK last year and claims to be a "first line treatment for major depression". Expand
Database processing for identification of concomitant drug frequencies in a forensic material positive for antidepressant drugs
TLDR
The drugs dextropropoxyphene, ethanol, codeine, flunitrazepam, paracetamol, propiomazine and alimemazine were signifcantly more common as concomitant drugs in B-cases than in C-cases (non‑intoxications). Expand
...
1
2
...

References

SHOWING 1-10 OF 19 REFERENCES
Clinical and experimental aspects of interactions between amine oxidase inhibitors and amine re-uptake inhibitors.
TLDR
Interactions could be avoided even with the 5-HT re-uptake inhibitors, by combination with relatively selective MAO A or B inhibitors, an approach with potential clinical value. Expand
Review of Cimetidine Drug Interactions
TLDR
Cimetidine, through its effect on gastric pH, may increase the absorption of acid-labile drugs or may decrease theabsor of drugs, and there have been reports of increased potential for myelosuppression when cimetidine is administered concurrently with drugs capable of causing bone marrow suppression. Expand
Cimetidine alters the disposition kinetics of the monoamine oxidase‐A inhibitor moclobemide
TLDR
The absolute oral bioavailability of moclobemide increased significantly after cimetidine administration, as did the maximum plasma concentration after a single oral dose, and the percentage change in clearance was essentially independent of the corresponding initial control clearance value. Expand
Adverse consequences of fluoxetine-MAOI combination therapy.
The authors describe two series of patients: 12 treated simultaneously with fluoxetine and a monoamine oxidase inhibitor and 6 patients started on treatment with an MAOI 10 days or more afterExpand
Disposition kinetics of moclobemide, a monoamine oxidase‐A enzyme inhibitor: Single and multiple dosing in normal subjects
TLDR
The absorption and disposition kinetics of moclobemide (Ro 11‐1163), a new reversible and preferential monoamine oxidase‐A enzyme inhibitor, were examined in 12 normal male subjects, finding a reduced metabolic, presumably hepatic, clearance that may be the result of self‐inhibition or metabolite inhibition of mClobemid clearance. Expand
Monoamine oxidase inhibitors and anaesthesia. A review.
TLDR
There has been a recent renewal of interest in the use of monoamine oxidase inhibitors in psychiatry, and the interaction with pethidine has two distinct forms-"excitatory" and "depressive". Expand
Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A.
TLDR
The neurochemical profile of moclobemide indicates clearly that this nonhydrazine nonhepatotoxic MAO-A inhibitor represents a novel and safe drug for treatment of affective disorders. Expand
The effects of moclobemide on cognition.
TLDR
Moclobemide would appear to have an advantage over antidepressant compounds such as the tricyclics of having a lower liability to impair cognitive efficiency, however, to establish this in depressed patients it will be necessary to incorporate sensitive assessments of cognitive efficiency into trials of the drug in young and elderly populations. Expand
Biotransformation of moclobemide in humans
TLDR
The structure of the urinary metabolites formed after moclobemide administration in humans was elucidated, and the pattern compared with that in the plasma was found to be qualitatively but not quantitatively similar to that observed in urine. Expand
UNALTERED IBUPROFEN-INDUCED FAECAL BLOOD LOSS UPON COADMINISTRATION OF MOCLOBEMIDE
TLDR
The results demonstrate that the concomitant administration of ibuprofen and moclobemide to healthy volunteers does not result in a clinically significant interaction, either at the pharmacodynamic (faecal blood loss) or at the Pharmacokinetic level. Expand
...
1
2
...